中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 10
Oct.  2023
Turn off MathJax
Article Contents

Further discussion on the antiviral treatment of chronic hepatitis B patients with indeterminate phase

DOI: 10.3969/j.issn.1001-5256.2023.10.001
More Information
  • Corresponding author: ZHUANG Hui, zhuangbmu@126.com (ORCID: 0000-0001-9119-6325)
  • Received Date: 2023-09-14
  • Published Date: 2023-10-30
  • This paper discusses further on the antiviral treatment of chronic hepatitis B patients with indeterminate phase. These patients have a high proportion of significant necroinflammation and fibrosis in the liver, and a higher risk of disease progression compared with those with true HBeAg-positive chronic hepatitis B virus (HBV) infection (formerly called the immune tolerance phase) or HBeAg-negative chronic HBV infection (formerly called the immune control phase). Antiviral therapy may reduce the risk of HBV-related hepatocellular carcinoma in chronic hepatitis B patients with indeterminate phase.

     

  • loading
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Experts opinon on expanding anti-HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30( 2): 131- 136. DOI: 10.3760/cma.j.cn501113-20220209-00060.

    中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30( 2): 131- 136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Hepatol, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma.j.cn501113-20221204-00607.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 12): 1309- 1331. DOI: 10.3760/cma.j.cn501113-20221204-00607.
    [3]
    KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134( 5): 1376- 1384. DOI: 10.1053/j.gastro.2008.02.075.
    [4]
    HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59( 4): 865- 871. DOI: 10.1007/s10620-014-3054-1.
    [5]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [6]
    MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1766- 1775. DOI: 10.1016/j.cgh.2021.07.036.
    [7]
    CHOI HSJ, TONTHAT A, JANSSEN HLA, et al. Aiming for functional cure with established and novel therapies for chronic hepatitis B[J]. Hepatol Commun, 2022, 6( 5): 935- 949. DOI: 10.1002/hep4.1875.
    [8]
    DUSHEIKO G, AGARWAL K, MAINI MK. New approaches to chronic hepatitis B[J]. N Engl J Med, 2023, 388( 1): 55- 69. DOI: 10.1056/NEJMra2211764.
    [9]
    YAO KF, LIU JC, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28( 7): 1025- 1033. DOI: 10.1111/jvh.13511.
    [10]
    DUAN MH, CHI XL, XIAO HM, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15( 2): 318- 327. DOI: 10.1007/s12072-021-10153-2.
    [11]
    HUANG DQ, LI XH, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1803- 1812.e 5. DOI: 10.1016/j.cgh.2021.01.019.
    [12]
    JIANG SW, LIAN X, HU AR, et al. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication[J]. World J Gastroenterol, 2023, 29( 16): 2479- 2494. DOI: 10.3748/wjg.v29.i16.2479.
    [13]
    WANG J, YAN XM, ZHU L, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone[J]. Aliment Pharmacol Ther, 2023, 57( 5): 464- 474. DOI: 10.1111/apt.17272.
    [14]
    XU XQ, WANG H, SHAN S, et al. The impact of the definitions of clinical phases on the profiles of grey-zone patients with chronic hepatitis B virus infection[J]. Viruses, 2023, 15( 5): 1212. DOI: 10.3390/v15051212.
    [15]
    JU YH, HAN GR, ZHANG P, et al. Staging and clinical characteristics of pregnant women with chronic hepatitis B virus infection: A retrospective cohort study from Nanjing, China[J]. J Obstet Gynaecol Res, 2023, 49( 10): 2427- 2435. DOI: 10.1111/jog.15753.
    [16]
    LIU JC, WANG J, YAN XM, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis[J]. Hepatol Commun, 2022, 6( 4): 855- 866. DOI: 10.1002/hep4.1859.
    [17]
    CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50( 2): 215- 226. DOI: 10.1111/apt.15311.
    [18]
    KIM GA, HAN S, CHOI GH, et al. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients[J]. Aliment Pharmacol Ther, 2020, 51( 11): 1169- 1179. DOI: 10.1111/apt.15725.
    [19]
    TENG W, CHANG TT, YANG HI, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines[J]. Hepatol Int, 2021, 15( 6): 1421- 1430. DOI: 10.1007/s12072-021-10263-x.
    [20]
    SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10( 1): 1- 98. DOI: 10.1007/s12072-015-9675-4.
    [21]
    HUANG DQ, TRAN A, YEH ML, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78( 5): 1558- 1568. DOI: 10.1097/HEP.0000000000000459.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Article Metrics

    Article views (495) PDF downloads(214) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return